Wolfgang Miesbach /LinkedIn
Sep 16, 2025, 02:44
Wolfgang Miesbach Highlights First Inhibitor Case After Hemophilia A Gene Therapy (Giroctocogene Fitelparvovec)
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“First reported inhibitor development in haemophilia A gene therapy Presented by Davide Matino at BIC meeting at Phase 3 giroctocogene fitelparvovec (AAV6, 3×10¹³ vg/kg, n=74).
Patient Profile:
- Genetic: Intron 22 inversion
- History: ITP + splenectomy
- Comorbidities: HCV & HIV co-infection
- Experience: 6,000 exposure days with FVIII
Clinical Timeline:
- Peak FVIII (day 75 after gene therapy): 441.7%
- Post-infusion: Multiple steroid courses for ↑ALT/AST
- Inhibitor development more than 1 year after treatment”
More recent insights on Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?